Skip to main content

Table 4 Occurrence of irAEs and AEs of any grade, Grade 3/4 and leading to treatment discontinuation across body mass index categories according to the WHO classification

From: Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

 

BMI category

Adverse events

Underweight

Normal weight

Overweight

Obese

P*

Any irAEs, n (%)

5 (41.7)

33 (50.8)

16 (51.6)

13 (56.5)

0.87

G3/G4 irAEs, n (%)

2 (16.7)

13 (20)

5 (16.1)

6 (27.3)

0.78

Any AEs, n (%)

4 (33.3)

17 (26.2)

10 (32.3)

11 (45.8)

0.37

G3/G4 AEs, n (%)

3 (25)

7 (10.8)

7 (22.6)

4 (16.7)

0.38

LDT irAEs, n (%)

2 (16.7)

3 (4.8)

2 (6.5)

4 (17.4)

0.20

LTD AEs, n (%)

0

3 (4.7)

2 (6.5)

0

0.54

  1. WHO World Health Organization, BMI body mass index, irAE immune-related adverse event, G grade, AE immune non-related adverse event, LTD leading to treatment discontinuation
  2. *Pearson Chi-Square
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us